| The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04854759 |
Recruitment Status : Recruiting First Posted : April 22, 2021 Last Update Posted : April 27, 2021 |
Sponsor:
Independent Public Clinical Hospital No. 4 in Lublin
Information provided by (Responsible Party):
Independent Public Clinical Hospital No. 4 in Lublin
Brief Summary:
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| COVID-19SARS-CoV-2 | Drug: Amantadine HydrochlorideDrug: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus |
| Actual Study Start Date : | March 15, 2021 |
| Estimated Primary Completion Date : | March 31, 2022 |
| Estimated Study Completion Date : | May 31, 2022 https://www.clinicaltrials.gov/ct2/show/NCT04854759?term=Amantadine&draw=2&rank=47 |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.